The FDA has approved Kirsty (Biocon), a biosimilar to rapid-acting insulin aspart (NovoLog) , for treatment of type 1 or type 2 diabetes. Kirsty is the first rapid-acting insulin to become available in the US…
Med Lett Drugs Ther. 2025 Nov 10; 67(1741):e185-6 doi:10.58347/tml.2025.1741g
The FDA has approved Kirsty (Biocon), a biosimilar to rapid-acting insulin aspart (NovoLog) , for treatment of type 1 or type 2 diabetes. Kirsty is the first rapid-acting insulin to become available in the US that has received interchangeability status with NovoLog ; Merilog , another insulin aspart biosimilar, was approved earlier but has not received interchangeability status with NovoLog .
The FDA has approved Merilog (Sanofi), a biosimilar to rapid-acting insulin aspart (NovoLog) , for treatment of patients with type 1 or type 2 diabetes. Merilog is the first rapid-acting insulin biosimilar…
Med Lett Drugs Ther. 2025 Jun 23; 67(1731):104 doi:10.58347/tml.2025.1731c
The FDA has approved Merilog (Sanofi), a biosimilar to rapid-acting insulin aspart (NovoLog) , for treatment of patients with type 1 or type 2 diabetes. Merilog is the first rapid-acting insulin biosimilar product to become available in the US.
Omlyclo (omalizumab-igec; Celltrion), a biosimilar product interchangeable with the recombinant anti-IgE monoclonal antibody Xolair , has been approved by the FDA for same indications as Xolair (see Table 1).…
Med Lett Drugs Ther. 2025 Jun 9; 67(1730):95-6 doi:10.58347/tml.2025.1730f
Omlyclo (omalizumab-igec; Celltrion), a biosimilar product interchangeable with the recombinant anti-IgE monoclonal antibody Xolair , has been approved by the FDA for same indications as Xolair (see Table 1). Omlyclo is the first Xolair biosimilar to be approved in the US.
The FDA has approved ustekinumab-auub ( Wezlana – Amgen), an interchangeable biosimilar product similar to the interleukin-12 and -23 antagonist Stelara , for treatment of the same indications as Stelara…
Med Lett Drugs Ther. 2024 Jul 22; 66(1707):119 doi:10.58347/tml.2024.1707e
The FDA has approved ustekinumab-auub ( Wezlana – Amgen), an interchangeable biosimilar product similar to the interleukin-12 and -23 antagonist Stelara , for treatment of the same indications as Stelara (see Table 1). Wezlana is the first Stelara biosimilar to be approved in the US.
The FDA has approved the oral Janus kinase (JAK) inhibitor upadacitinib ( Rinvoq – Abbvie) for treatment of moderately to severely active ulcerative colitis in adults who have had an inadequate response to…
Med Lett Drugs Ther. 2022 Sep 5; 64(1658):142-4
The FDA has approved the oral Janus kinase (JAK) inhibitor upadacitinib ( Rinvoq – Abbvie) for treatment of moderately to severely active ulcerative colitis in adults who have had an inadequate response to or cannot tolerate one or more tumor necrosis factor (TNF) inhibitors. Upadacitinib is the second JAK inhibitor to be approved for this indication; tofacitinib (Xeljanz) was the first. Upadacitinib is also approved for treatment of rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and ankylosing spondylitis.
Insulin glargine-yfgn ( Semglee – Viatris), a follow-on insulin glargine product, has now received interchangeability status with the reference product Lantus from the FDA. It is the first biosimilar insulin…
Med Lett Drugs Ther. 2021 Oct 4; 63(1634):159-60
Insulin glargine-yfgn ( Semglee – Viatris), a follow-on insulin glargine product, has now received interchangeability status with the reference product Lantus from the FDA. It is the first biosimilar insulin product to receive this designation in the US. Now a pharmacist can substitute Semglee for Lantus as a lower-cost alternative without permission from the prescriber.
Psoriatic arthritis is a chronic inflammatory arthropathy associated with psoriasis. A recent review found that about 20% of patients with psoriasis have psoriatic arthritis. Updated guidelines for treatment…
Med Lett Drugs Ther. 2019 Dec 30; 61(1588):203-10
Psoriatic arthritis is a chronic inflammatory arthropathy associated with psoriasis. A recent review found that about 20% of patients with psoriasis have psoriatic arthritis. Updated guidelines for treatment of psoriatic arthritis have recently been published.
Tildrakizumab-asmn ( Ilumya – Sun), an interleukin (IL)-23 antagonist, has been approved by the FDA for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or…
Med Lett Drugs Ther. 2019 Jan 14; 61(1563):4-6
Tildrakizumab-asmn ( Ilumya – Sun), an interleukin (IL)-23 antagonist, has been approved by the FDA for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Tildrakizumab is the second selective IL-23 antagonist to be approved for this indication; guselkumab (Tremfya) was the first.
The FDA has approved the interleukin (IL)-6 inhibitor sarilumab ( Kevzara – Sanofi) for second-line treatment of adults with moderately to severely active rheumatoid arthritis (RA). It is the second IL-6…
Med Lett Drugs Ther. 2017 Aug 14; 59(1527):134-6
The FDA has approved the interleukin (IL)-6 inhibitor sarilumab ( Kevzara – Sanofi) for second-line treatment of adults with moderately to severely active rheumatoid arthritis (RA). It is the second IL-6 inhibitor to be approved for this indication; tocilizumab (Actemra) was approved earlier.
The FDA has approved infliximab-dyyb ( Inflectra – Pfizer; marketed as Remsima in some countries), as a biosimilar of the TNF inhibitor infliximab (Remicade) . Infliximab-dyyb was approved in the European…
Med Lett Drugs Ther. 2017 Jan 30; 59(1513):23-5
The FDA has approved infliximab-dyyb ( Inflectra – Pfizer; marketed as Remsima in some countries), as a biosimilar of the TNF inhibitor infliximab (Remicade) . Infliximab-dyyb was approved in the European Union (EU) in 2013 and in Canada in 2014. It is the second biosimilar to be approved by the FDA. Filgastrim-sndz (Zarxio) , a recombinant human granulocyte colony-stimulating factor, was the first.
The FDA has approved filgrastim-sndz ( Zarxio – Sandoz), a biosimilar of the recombinant human granulocyte colony-stimulating factor filgrastim (G-CSF; Neupogen ), which has been available in the US since…
Med Lett Drugs Ther. 2016 Mar 14; 58(1490):34-5
The FDA has approved filgrastim-sndz ( Zarxio – Sandoz), a biosimilar of the recombinant human granulocyte colony-stimulating factor filgrastim (G-CSF; Neupogen ), which has been available in the US since 1991. Zarxio is the first biosimilar product to be approved in the US; it has been available in Europe as Zarzio since 2009.
The FDA has approved Toujeo (Sanofi), a more concentrated form of insulin glargine containing 300 IU/mL compared to the 100 IU/mL in Lantus (Sanofi). Lantus is nearing the end of its patent protection in the…
Med Lett Drugs Ther. 2015 May 11; 57(1468):69-70
The FDA has approved Toujeo (Sanofi), a more concentrated form of insulin glargine containing 300 IU/mL compared to the 100 IU/mL in Lantus (Sanofi). Lantus is nearing the end of its patent protection in the US, and biosimilars are expected to become available.